Spruce Biosciences, Inc. (SPRB)

NCM – Цена в реальном времени. Валюта: USD

56.66

+0.26 (0.47%)

При закрытии: May 12, 2026, 4:00 PM EDT

55.15

-1.51 (-2.67%)

До открытия: May 13, 2026, 5:58 AM EDT

04.05.2026

Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointments of Brian Walls as Vice President, Market Access and Darren M. Johnson as Vice President, Commercial Operations. Mr. Walls brings more than 20 years of biopharmaceutical commercial leadership experience and has contribu.

21.04.2026

Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (“Spruce Biosciences”) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the pricing of its previously announced underwritten public offering of 1,150,000 shares of its common stock at a price to the public of $50.00 per share and, in lieu of shares of common stock to a certain invest.

20.04.2026

Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (“Spruce Biosciences”) (NASDAQ: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that it has commenced an underwritten public offering of shares of its common stock or pre-funded warrants to purchase shares of its common stock in lieu thereof. All of the securities are being offered by Spruce.

03.04.2026

Wall Street Analysts Believe Spruce Biosciences (SPRB) Could Rally 181.21%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 181.2% in Spruce Biosciences (SPRB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

18.03.2026

Does Spruce Biosciences (SPRB) Have the Potential to Rally 208.32% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 208.3% in Spruce Biosciences (SPRB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

09.03.2026

Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2025 and provided corporate updates. “2025 was a very productive year, and our team continues to execute and drive towards key milestones with our tralesinidase alfa enzyme replacement t.

09.03.2026

Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Dale Hooks as Chief Commercial Officer. Mr. Hooks joins the company with nearly 35 years of pharmaceutical marketing and sales experience, including commercial leadership roles for 21 new product launches. Mr. Hooks.

Видео

No Data

There is no data to display

Пресс-релизы

04.05.2026

Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations

21.04.2026

Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

20.04.2026

Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

09.03.2026

Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2025 and provided corporate updates. “2025 was a very productive year, and our team continues to execute and drive towards key milestones with our tralesinidase alfa enzyme replacement t.

Spruce Biosciences, Inc. (SPRB)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Spruce Biosciences, Inc. (SPRB)

Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations

Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Wall Street Analysts Believe Spruce Biosciences (SPRB) Could Rally 181.21%: Here's is How to Trade

Does Spruce Biosciences (SPRB) Have the Potential to Rally 208.32% as Wall Street Analysts Expect?

Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates

Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer

Видео

No Data

Пресс-релизы

Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations

Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates

Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations

Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Wall Street Analysts Believe Spruce Biosciences (SPRB) Could Rally 181.21%: Here's is How to Trade

Does Spruce Biosciences (SPRB) Have the Potential to Rally 208.32% as Wall Street Analysts Expect?

Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates

Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer

Видео

No Data

Пресс-релизы

Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations

Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates

Search stocks

Spruce Biosciences, Inc. (SPRB)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Spruce Biosciences, Inc. (SPRB)

Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations

Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Wall Street Analysts Believe Spruce Biosciences (SPRB) Could Rally 181.21%: Here's is How to Trade

Does Spruce Biosciences (SPRB) Have the Potential to Rally 208.32% as Wall Street Analysts Expect?

Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates

Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer

Видео

No Data

Пресс-релизы

Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations

Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates

Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations

Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Wall Street Analysts Believe Spruce Biosciences (SPRB) Could Rally 181.21%: Here's is How to Trade

Does Spruce Biosciences (SPRB) Have the Potential to Rally 208.32% as Wall Street Analysts Expect?

Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates

Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer

Видео

No Data

Пресс-релизы

Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations

Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates